457 related articles for article (PubMed ID: 34831031)
1. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
3. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
4. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
5. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
[TBL] [Abstract][Full Text] [Related]
6. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
7. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
[TBL] [Abstract][Full Text] [Related]
8. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
9. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
10. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease.
Wang C; Zhu C; Shao L; Ye J; Shen Y; Ren Y
Mediators Inflamm; 2019; 2019():7659509. PubMed ID: 31341422
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
12. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
13. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.
Cheng Z; Chen Y; Schnabl B; Chu H; Yang L
J Adv Res; 2024 May; 59():173-187. PubMed ID: 37356804
[TBL] [Abstract][Full Text] [Related]
14. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
[TBL] [Abstract][Full Text] [Related]
15. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
[TBL] [Abstract][Full Text] [Related]
16. Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling.
Ren ZL; Li CX; Ma CY; Chen D; Chen JH; Xu WX; Chen CA; Cheng FF; Wang XQ
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361829
[TBL] [Abstract][Full Text] [Related]
17. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis.
Yang C; Wan M; Xu D; Pan D; Xia H; Yang L; Sun G
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639207
[TBL] [Abstract][Full Text] [Related]
18. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
[TBL] [Abstract][Full Text] [Related]
19. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
Gottlieb A; Canbay A
Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
[TBL] [Abstract][Full Text] [Related]
20. Role of FXR in the development of NAFLD and intervention strategies of small molecules.
Long J; Xu Y; Zhang X; Wu B; Wang C
Arch Biochem Biophys; 2024 Jul; 757():110024. PubMed ID: 38703803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
